The Dominican Republic production shift at AJR is still waiting on customer qualification, so its cost-benefit has not yet reached the margins.
UFPT UFP Technologies Inc
XNAS
323.90
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
UFPT
$323.90
—
What changed
Recent filings, trades and movesKey stats
$323.90
- 52-Week Range
- $173.86 – $342.11
- YTD
- +44.99%
- IV Rank (30D)
- 44.48
- Straddle Price
- $36.60
- P/C Vol Ratio
- 1.03
- Market Cap
- $2.4B
- Open
- $309.36
- Day Range
- $303.58 – $325.76
- Volume
- 49,252
- Prev Close
- $303.47
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.03 |
| Cost of Equity (CAPM) | 9.80% (VRP-adj) |
| WACC | 10.19% |
| Volatility Risk Premium | -11.5pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 18.4% |
| Rev. Growth (YoY, DCF input) | +12.6% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 15.6% |
| Book / Price | 19.6% |
| Gross Margin (TTM) | 28.5% |
| FCF Margin (TTM) | 9.7% |
| Debt / Equity | 0.23 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +22.0% (reverse-DCF on current price) |
| SMA 50 | $291.21 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $294.26 |
| Bollinger Width / SMA20 | 13.3% (drives anchor stability) |
| Net Debt | $0.1B |
| Market Cap | $2B |
Peers used for multiples: ADMA, ATEC, HALO, IONS, LGND, RARE, RGEN, TMDX
60-Day Conviction
14%
20-Day Fair Value
≈ by Dec 8, 2026
$324.16
α -0.5%
rank 44%
conviction
36%
40-Day Fair Value
≈ by Jan 6, 2027
$329.36
α +1.1%
rank 22%
conviction
40%
60-Day Fair Value
≈ by Feb 4, 2027
$327.43
α +0.5%
rank 32%
conviction
14%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $173.95 | 21% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $260.20 | 10% | median 25.5× · 4 peers |
| Peer EV/EBITDA | $439.56 | 10% | median 27.5× · 6 peers |
| Peer P/B | $426.32 | 2% | median 7.2× · 7 peers |
| Peer P/S | $584.36 | 6% | median 6.5× · 8 peers |
| Market Anchor (SMA50) | $291.21 | 35% | stability 83% (BB-width) |
| Options Expected (B-L 30d) | $304.96 | 16% | 15 strikes · skew +0.76 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $2.4B
- Employees
- 5,349
- List Date
- 1993-12-23
- CIK
- 0000914156
- Last Earnings
- Aug 3 after close · +25.2% vs ±8.9% expected
- Headquarters
- Newburyport, MA
- Homepage
- https://www.ufpt.com
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound c…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 0.94% | 0.20% | -1.60% | 1.60% | 11.55% | 12.42% | 4.18% |
| Feb | 5.88% | -3.00% | 6.97% | 17.30% | -15.97% | -17.70% | -1.09% |
| Mar | -5.05% | -1.24% | 10.07% | 16.33% | -6.29% | -5.24% | 1.43% |
| Apr | -4.79% | 1.72% | 7.97% | -17.90% | 2.26% | -1.22% | -1.99% |
| May | 8.66% | 10.40% | 11.14% | 10.40% | 10.30% | 13.41% | 10.72% |
| Jun | 2.33% | 3.45% | 22.33% | 1.09% | 5.15% | 21.55% | 9.32% |
| Jul | 3.35% | 1.60% | -0.88% | 11.24% | -10.29% | -6.42% | -0.23% |
| Aug | 15.27% | 15.85% | -8.20% | 4.78% | -7.24% | 11.37% | 5.30% |
| Sep | -10.79% | -6.30% | -7.95% | -3.24% | -3.84% | 0.94% | -5.20% |
| Oct | 0.05% | 7.06% | -2.54% | -13.37% | -3.47% | -3.56% | -2.64% |
| Nov | 7.22% | 29.27% | 21.80% | 18.44% | 13.89% | 14.38%* | 17.50% |
| Dec | 8.71% | -3.61% | 3.22% | -20.47% | 0.22% | -- | -2.39% |
| Total | 33.15% | 64.06% | 74.54% | 16.91% | -8.15% | 38.54% | 36.51% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $295.76
SMA 50: $291.73
SMA 200: $250.54
Current: $325.76
EMA 12: $301.39
EMA 26: $296.95
MACD: 4.4332 | Signal: 2.9308
BULLISH
ADX (14): 21.48
WEAK TREND
+DI: 34.23
−DI: 13.89
Momentum Oscillators
RSI (14): 61.36
NEUTRAL
Stoch %K: 49.57
Stoch %D: 47.74
Williams %R: -25.42
Volume & Volatility
BB Upper: $319.70
BB Lower: $271.82
OVERBOUGHT
OBV: 1,746,294
Vol SMA 20: 115,137
Vol ROC: -40.46%
ATR: $15.56
True Range: $22.29
HV 20: 77.2%
HV 30: 64.9%
HV 60: 48.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before UFPT’s Nov 3 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with confidence level (6/10)
Key Drivers: Strong momentum indicators, positive news sentiment, and low risk profile
Primary Risks: Overbought RSI, potential for mean reversion
Investment Thesis: UFPT is a strong performer in the industry, driven by its innovative products and strategic partnerships. The stock has shown remarkable resilience despite some recent volatility.
Recent News Sentiment Impact: Positive news sentiment from recent headlines contributes to the overall bullish tone.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Bullish
Support/Resistance Levels: Key levels include:
- Lower band: $211.12
- Middle line: $231.84
- Upper band: $252.57
Momentum Signals:
- RSI interpretation: Overbought (>70), potential for mean reversion
- MACD signal: Bullish (crossover above signal line)
- Bollinger Bands position: Squeeze, breakout possible
Volume Analysis: Volume trends and institutional interest signals indicate:
- Volume SMA 20: 196932.25 (stable)
- On-Balance Volume (OBV): 3025664.41 (strong uptrend)
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines from recent announcements and analyst upgrades contribute to the overall bullish tone.
Sentiment Assessment: Aggregate news sentiment is POSITIVE, with most headlines highlighting the company's innovative products and strategic partnerships.
Catalyst Identification: No imminent catalysts are identified, but the upcoming earnings report could provide further guidance on the company's performance.
Market Narrative: The technical signals align with the positive news sentiment, indicating a strong uptrend.
Risk & Volatility Assessment
Beta Interpretation: Beta is above average (1.07), indicating higher volatility than the market.
Volatility Regime: Current volatility levels are higher than historical norms (0.44).
Options Market Signals:
- IV Rank: 46.4% (Medium)
- Put/Call Volume Ratio: 0.52 (Bullish sentiment)
Downside Protection: Support levels and risk management considerations include:
- Lower band: $211.12
- Stop-loss level: below $230
Market Context & Positioning
Sector Performance: UFPT's sector is performing well, with a relative strength index (RSI) of 0.65.
Institutional Activity: Volume patterns suggest institutional interest is increasing.
Correlation Analysis: The stock's correlation with the market is moderate (R-squared: 0.30).
Relative Valuation: UFPT is trading within its historical range, with no significant overvaluation or undervaluation detected.
Key Levels & Action Items
Critical Price Levels: Monitor the support/resistance levels:
- Lower band: $211.12
- Middle line: $231.84
- Upper band: $252.57
Breakout/Breakdown Levels: Technical levels that could trigger significant moves include:
- SMA 200: $218.75
- EMA 26: $231.68
Time-Sensitive Catalysts: No imminent catalysts are identified, but the upcoming earnings report could provide further guidance.
Risk Management: Consider stop-loss levels and position sizing considerations:
- Stop-loss level: below $230
- Position size: adjust based on risk tolerance
Generated
News
All UFPT news →
Margin gains and a shifting robotic surgery outlook shape the quarter.
Earnings History
10 of 14 under expected move
Avg Expected Move
8.68%
Avg Actual Move
6.97%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-02 | After-Close | 5.57% | 2.46% | 0.44x | Within |
| 2023-08-04 | After-Close | 4.77% | 0.81% | 0.17x | Within |
| 2023-11-09 | After-Close | 5.72% | 4.44% | 0.78x | Within |
| 2024-02-26 | After-Close | 6.98% | 4.49% | 0.64x | Within |
| 2024-05-01 | After-Close | 7.44% | 8.24% | 1.11x | Exceeded |
| 2024-08-02 | After-Close | 7.59% | 5.23% | 0.69x | Within |
| 2024-11-12 | After-Close | 3.62% | 8.37% | 2.31x | Exceeded |
| 2025-02-25 | Pre-Market | 13.99% | 9.37% | 0.67x | Within |
| 2025-05-07 | Pre-Market | 8.34% | 0.08% | 0.01x | Within |
| 2025-08-05 | Pre-Market | 13.81% | 6.40% | 0.46x | Within |
| 2025-11-03 | After-Close | 12.06% | 12.05% | 1.00x | Within |
| 2026-02-24 | After-Close | 13.24% | 0.17% | 0.01x | Within |
| 2026-05-04 | After-Close | 9.37% | 10.32% | 1.10x | Exceeded |
| 2026-08-03 | After-Close | 8.95% | 25.16% | 2.81x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
UFPT Options Activity & IV Rank
UFPT IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 42.7%
7-DTE IV: 41.4%
Expected Move: $36.60
7-DTE Move: $19.40
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 69
Put Volume: 71
P/C Volume: 1.029
NEUTRAL
Call OI: 73
Put OI: 83
P/C OI: 1.137
Total OI: 156
ATM Options Pricing
ATM Call: $18.70
ATM Put: $17.90
Call %: 5.8%
Put %: 5.5%
Chain Summary
Chain Volume: 140
Chain OI: 156
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 57th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
57%
vs own history
GEX tilt
+0.04
OI-weighted, today
Vanna tilt
-1.00
δ-sensitivity to IV
Charm tilt
+1.00
δ-decay vs time
Vanna tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)19.6LowNov 9
IV Rank (30 DTE)44.5MediumNov 9
Straddle Price (30 DTE)$36.60Nov 9
Beta Analysis
Risk Metrics
Beta: 1.6238
Alpha: 28.52%
Correlation: 0.4347
R-Squared: 18.9%
Stock Volatility: 51.5%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own UFPT
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $22.4M | #652 of 3138 | -20.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $12.3M | #651 of 4729 | -29.2% | 13F | |
| Point72 Hedge fund Steve Cohen | $5.7M | #944 of 1945 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $2.1M | #2887 of 6285 | -59.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
UFPT Institutional Ownership (13F)
Filings for 2026-06-30 · 144 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 7,792,750 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$1.33M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.33M | 100.00% | 2026-06-30 |
2 filers$1.25M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $901.44K | 72.34% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $344.67K | 27.66% | 2026-06-30 |
UFPT Insider Trading (Form 4)
Latest: 2026-08-27Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Marc D Kozin | Director | Sell (S) | −7,000 | $304.50 | -$2.13M | EDGAR |
| 2026-08-19 | Symeria Hudson | Director | Sell (S) | −298 | $319.11 | -$95.1K | EDGAR |
| 2026-08-17 | Cynthia L Feldmann | Director | Sell (S) | −1,000 | $324.26 | -$324.3K | EDGAR |
| 2026-08-17 | Symeria Hudson | Director | Mixed Sell −1,926 · Exer +1,196 |
−730 | $279.26 | -$378.4K | EDGAR |
| 2026-08-12 | Joseph John Hassett | Director | — | — | — | EDGAR | |
| 2026-08-11 | R Jeffrey Bailly | Executive Chairman | Sell (S) | −13,011 | $316.13 | -$4.11M | EDGAR |
| 2026-08-10 | R Jeffrey Bailly | Executive Chairman | Sell (S) | −15,695 | $318.38 | -$5.00M | EDGAR |
| 2026-08-07 | Jason Holt | Vice President | Sell (S) | −1,100 | $317.00 | -$348.7K | EDGAR |
| 2026-06-15 | Cynthia L Feldmann | Director | Mixed Exer +1,200 · Sell −1,200 |
— | $141.62 | -$234.4K | EDGAR |
| 2026-06-08 | Joseph John Hassett | Director | Award (A) | +802 | — | EDGAR | |
| 2026-06-08 | Symeria Hudson | Director | Award (A) | +802 | — | EDGAR | |
| 2026-06-08 | Ryan K Stafford | SVP Human Resources | Award (A) | +1,448 | — | EDGAR | |
| 2026-06-08 | Cynthia L Feldmann | Director | Award (A) | +802 | — | EDGAR | |
| 2026-06-08 | Thomas Oberdorf | Director | Award (A) | +802 | — | EDGAR | |
| 2026-06-08 | R Jeffrey Bailly | Executive Chairman | Mixed Grant +1,787 · Tax −750 |
+1,037 | $223.87 | -$167.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
UFPT Insider Holdings
13 insiders · @ $325.76
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | R Jeffrey Bailly | Executive Chairman | 171,200 | $55.77M | -$101.36M | 145 | 2026-08-11 |
| 2 | Ronald J Lataille | Chief Financial Officer | 59,417 | $19.36M | -$11.73M | 72 | 2026-06-08 |
| 3 | Mitchell Rock | President | 39,115 | $12.74M | -$3.58M | 68 | 2026-06-08 |
| 4 | Marc D Kozin | Director | 24,462 | $7.97M | -$3.25M | 35 | 2026-08-27 |
| 5 | Thomas Oberdorf | Director | 13,219 | $4.31M | -$6.99M | 43 | 2026-06-08 |
| 6 | Christopher P. Litterio | Senior Vice President | 11,977 | $3.90M | -$2.19M | 27 | 2026-03-04 |
| 7 | Jason Holt | Vice President | 7,878 | $2.57M | -$482.7K | 17 | 2026-08-07 |
| 8 | Steve Cardin | Vice President | 5,623 | $1.83M | -$180.7K | 11 | 2025-03-05 |
| 9 | Cynthia L Feldmann | Director | 4,476 | $1.46M | -$2.15M | 16 | 2026-08-17 |
| 10 | Joseph John Hassett | Director | 2,602 | $847.6K | $0 | 6 | 2026-08-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
UFPT Board & Officers
As of SEC filings through Aug 27, 2026Directors 7
- R Jeffrey Bailly · on file since 2006
- Marc D Kozin · since Jun 8, 2006
- Thomas Oberdorf · on file since Jun 2006
- Daniel C Croteau · since Dec 16, 2015
- Cynthia L Feldmann · since Jun 6, 2017
- Joseph John Hassett · since Jun 8, 2022
- Symeria Hudson · since Jun 8, 2022
Officers 5
- Jason Holt · Vice President · since Jun 9, 2021
- Mitchell Rock · President · listed since Feb 2024
- Ronald J Lataille · Chief Financial Officer · on file since 2006
- Ryan K Stafford · SVP Human Resources · since Jun 4, 2026
- R Jeffrey Bailly · Executive Chairman · listed since Jun 2026
Changes in the last 10 years (13)
| Jun 8, 2026 | R Jeffrey Bailly listed as Executive Chairman (previously CEO) in SEC filings |
| Jun 4, 2026 | Ryan K Stafford became SVP Human Resources |
| May 19, 2026 | The company announced the departure of Christopher P. Litterio as Senior Vice President in an SEC filing |
| Mar 15, 2025 | The company announced the departure of Steve Cardin as Vice President in an SEC filing |
| Feb 8, 2024 | R Jeffrey Bailly listed as CEO (previously President and CEO) in SEC filings |
| Feb 8, 2024 | Mitchell Rock listed as President (previously Vice President) in SEC filings |
| Jun 8, 2022 | Symeria Hudson became a director |
| Jun 8, 2022 | Joseph John Hassett became a director |
| Feb 3, 2022 | Daniel J Shaw reported in an SEC filing no longer being Vice President |
| Jun 9, 2021 | Steve Cardin became Vice President |
| Jun 9, 2021 | Jason Holt became Vice President |
| Nov 6, 2017 | Christopher P. Litterio became Senior Vice President |
| Jun 6, 2017 | Cynthia L Feldmann became a director |
Not reported recently (4)
- Robert W Pierce Jr · Last reported as a director in an SEC filing dated Jun 11, 2021
- Lucia Luce Quinn · Last reported as a director in an SEC filing dated Jun 11, 2021
- W David Smith · Last reported as Vice President in an SEC filing dated Mar 3, 2020
- David K Stevenson · Last reported as a director in an SEC filing dated May 8, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
UFPT Proposed Insider Sales (Form 144)
Latest: 2026-08-25
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
3 filings
· $3.1M notice value
· 3 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
KOZIN MARC D (1, $2.1M) · Symeria Hudson (1, $625K) · Cynthia Feldmann (1, $324K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-25 | KOZIN MARC D | Director | 7,000 | $2.14M | 2026-08-25 | Fidelity Brokerage Services | — | EDGAR |
| 2026-08-17 144/A | Symeria Hudson | Member of Board of Directors | 2,224 | $625.1K | 2026-08-14 | Merrill Lynch | — | EDGAR |
| 2026-08-13 | Cynthia Feldmann | Board of Director Member | 1,000 | $324.3K | 2026-08-13 | Merrill Lynch | — | EDGAR |
| 2026-08-06 | Litterio Christopher P. | Officer | 1,000 | $322.0K | 2026-08-06 | Raymond James & Associates | — | EDGAR |
| 2026-08-06 | John B. Bailly as Trustee of The R. Jeffrey Bailly Irrevocable Trust of 2022 | Affiliate | 28,706 | $9.20M | 2026-08-06 | Charles Schwab Corp | — | EDGAR |
| 2026-08-06 | Jason D Holt | Officer | 1,100 | $348.7K | 2026-08-06 | Merrill Lynch | — | EDGAR |
| 2026-06-12 | Cynthia Feldmann | Board Member | 1,200 | $287.1K | 2026-06-12 | Merrill Lynch | — | EDGAR |
| 2026-05-12 | Daniel Croteau | Director | 2,864 | $635.0K | 2026-05-12 | UBS Financial Services Inc | — | EDGAR |
| 2025-12-10 | Holt Jason | Officer | 100 | $21.0K | 2025-12-10 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2025-11-05 | Litterio Christopher P. | Officer | 1,829 | $426.2K | 2025-11-06 | Raymond James & Associates | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
87 ETFs hold UFPT
25 shown · $495.50M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.14% | $142.2M | $103.8B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $69.6M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.08% | $59.9M | $76.6B | 2026-11-06 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.03% | $25.9M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.16% | $21.8M | $13.7B | 2026-11-06 |
| 6 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.29% | $21.2M | $7.3B | 2026-11-06 |
| 7 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.13% | $21.2M | $15.7B | 2026-11-05 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.05% | $17.7M | — | 2026-11-05 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.07% | $13.2M | — | 2026-09-30 |
| 10 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.29% | $13.1M | $4.6B | 2026-11-05 |
| 11 | CSMD Congress SMid Growth ETF | Nport | 2.63% | $11.9M | — | 2026-07-31 |
| 12 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $11.0M | — | 2026-08-31 |
| 13 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $9.4M | — | 2026-11-05 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.12% | $8.8M | — | 2026-11-05 |
| 15 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.13% | $8.1M | — | 2026-09-30 |
| 16 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.54% | $7.1M | $1.3B | 2026-11-06 |
| 17 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.7M | — | 2026-09-30 |
| 18 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.14% | $4.6M | $3.2B | 2026-11-05 |
| 19 | PSC Principal U.S. Small-Cap ETF | Nport | 0.18% | $4.1M | — | 2026-06-30 |
| 20 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.25% | $3.5M | $1.4B | 2026-11-06 |
| 21 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $3.2M | — | 2026-11-05 |
| 22 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $3.0M | $93.2B | 2026-11-06 |
| 23 | VIOG Vanguard S&P Small-Cap 600 Growth ETF | Vanguard | 0.29% | $3.0M | — | 2026-11-05 |
| 24 | FSMD Fidelity Small-Mid Multifactor ETF | Fidelity | 0.11% | $2.8M | $2.4B | 2026-11-05 |
| 25 | DUSG Dimensional US Small Cap Growth ETF | Dimensional | 0.14% | $2.7M | — | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
35.08
TTM Diluted EPS
$9.26
TTM Revenue
$631.64M
TTM Net Income
$72.30M
TTM Op. Cash Flow
$71.58M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $173.96M | $20.85M | $2.68 | $15.61M |
| Q1 '26 | 2026-03-31 | $154.20M | $17.50M | $2.24 | $3.20M |
| Q4 '25 | 2025-12-31 | $148.91M | $17.57M | $2.23 | $16.84M |
| Q3 '25 | 2025-09-30 | $154.56M | $16.38M | $2.11 | $35.92M |
| Q2 '25 | 2025-06-30 | $151.18M | $17.18M | $2.21 | $25.33M |
| Q1 '25 | 2025-03-31 | $148.15M | $17.18M | $2.21 | $13.81M |
| Q4 '24 | 2024-12-31 | $144.07M | $16.38M | $2.09 | $24.42M |
| Q3 '24 | 2024-09-30 | $145.16M | $16.36M | $2.11 | $19.80M |
| Q2 '24 | 2024-06-30 | $110.18M | $13.55M | $1.75 | $11.95M |
| Q1 '24 | 2024-03-31 | $105.01M | $12.69M | $1.64 | $10.42M |
| Q4 '23 | 2023-12-31 | $101.50M | $11.61M | $1.50 | $12.46M |
| Q3 '23 | 2023-09-30 | $100.78M | $11.69M | $1.52 | $17.80M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
35.08
P/B
5.47
P/S
4.01
EV/EBITDA
22.57
EV/Sales
4.16
ROE
15.6%
ROA
10.6%
Div Yield
0.00%
FCF Yield
2.83%
Debt/Equity
0.23
Current Ratio
—
Market Cap
$2.53B
as of 2026-11-09
UFPT vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| HALO Halozyme Therapeutics, Inc. | $11.8B | 30.0 | +41.2% | +46.5% | 47 |
| RGEN Repligen Corp | $11.1B | — | +13.8% | +9.3% | 28 |
| IONS Ionis Pharmaceuticals, Inc. Common Stock | $6.6B | — | −7.4% | −61.4% | 68 |
| LGND Ligand Pharmaceuticals Inc. | $6.1B | 142.3 | +1.0% | +65.4% | 43 |
| TMDX TransMedics Group, Inc. Common Stock | $3.1B | 24.6 | +25.8% | −22.6% | 12 |
| ADMA ADMA Biologics, Inc. | $2.8B | 18.5 | +8.0% | −27.5% | 4 |
| UFPT UFP Technologies Inc | $2.4B | 35.2 | +7.3% | +45.8% | 44 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.6B | — | +15.8% | −30.8% | 18 |
| ATEC Alphatec Holdings, Inc. | $1.1B | — | +15.3% | −64.6% | 12 |
| Peer median | $4.6B | 27.3 | +14.6% | −25.0% | 23 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
980.95K
SI % of Float
13.29%
Days to Cover
8.70
Short Vol Ratio
77.2%
Free Float
7.38M
Float %
95.3%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-07